Highlights from the 2025 ASCO Annual Meeting: Part 2

Highlights from the 2025 ASCO Annual Meeting: Part 1

Redefining the Treatment Landscape: HER2-Low and Its Implications for HR+ HER2- Metastatic Breast Cancer

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

Katie Newlin, RN, MSN, AGPCNP-BC

Washington University in St. Louis/Siteman Cancer Center

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Intravenous Cancer Treatment Education

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Real-World Survival Outcomes by Risk Features in Patients with HR+, HER2− Early Breast Cancer in the US

Abemaciclib Clinical Management Guide

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER2-negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor: The CCTG/BCT MA.40/FINER study (NCT04650581)

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Journal of Clinical Oncology

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

Journal of Clinical Oncology

Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

HR+ HER2- Breast Cancer Resource Center

Highlights from the 2025 ASCO Annual Meeting: Part 2

Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer

Intravenous Cancer Treatment Education

Vaginal Estrogen Therapy Use and Survival in Females with Breast Cancer

Real-World Survival Outcomes by Risk Features in Patients with HR+, HER2− Early Breast Cancer in the US

Abemaciclib Clinical Management Guide

Clinical Cancer Research

Identification of early-stage breast cancer with minimal risk of recurrence by Breast Cancer Index

Cancers (Basel)

CDK4/6 as a therapeutic target in HR+/HER2- breast cancer cells—Current treatment status

The Breast

Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2- early breast cancer

Anticancer Research

Cardioprotective effect of pegfilgrastim on chemotherapy-induced cardiotoxicity in preoperative chemotherapy for breast cancer

Biomedicines

Real-world analysis of adherence to abemaciclib and endocrine therapy in women with HR+/HER2- breast cancer

Journal of Clinical Oncology

Journal of Clinical Oncology

VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer

Journal of Clinical Oncology

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC)

Journal of Clinical Oncology

Camizestrant + CDK4/6 inhibitor for the treatment of emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2– advanced breast cancer: Phase 3, double-blind ctDNA-guided SERENA-6 trial

Journal of Clinical Oncology

Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator’s choice standard endocrine therapy, or imlunestrant + abemaciclib: Results from the phase III EMBER-3 trial

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

First-Line Treatment for Metastatic ER+ HER2- Breast Cancer